The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Apr 2014
Randomized Controlled Trial Multicenter Study Clinical TrialEfficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial.
Approximately 5% to 10% of asthmatic patients achieve incomplete symptom control on current therapies. The association of IL-13 with asthma pathology and reduced corticosteroid sensitivity suggests a potential benefit of anti-IL-13 therapy in refractory asthma. GSK679586, a humanized mAb, inhibits IL-13 binding to both IL-13 receptor α1 and α2. ⋯ Although well tolerated, GSK679586 did not demonstrate clinically meaningful improvements in asthma control, pulmonary function, or exacerbations in patients with severe asthma. Further studies are needed to determine whether therapies targeting IL-13, the functionally related IL-4 cytokine, or both can provide clinical benefit in patients with severe refractory asthma or a subpopulation of these patients beyond that achievable with high-dose corticosteroids.
-
J. Allergy Clin. Immunol. · Apr 2014
Randomized Controlled TrialGuselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
IL-23 expression is increased in psoriatic lesions and might regulate TH17 T-cell counts in patients with psoriasis. ⋯ IL-23 inhibition with a single dose of guselkumab results in clinical responses in patients with moderate-to-severe psoriasis, suggesting that neutralization of IL-23 alone is a promising therapy for psoriasis.